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Abstract
The use of transgenic plants to produce novel products has great biotechnological potential as the relatively inexpensive
inputs of light, water, and nutrients are utilised in return for potentially valuable bioactive metabolites, diagnostic proteins
and vaccines. Extensive research is ongoing in this area internationally with the aim of producing plant-made vaccines of
importance for both animals and humans. Vaccine purification is generally regarded as being integral to the preparation of
safe and effective vaccines for use in humans. However, the use of crude plant extracts for animal immunisation may enable
plant-made vaccines to become a cost-effective and efficacious approach to safely immunise large numbers of farm animals
against diseases such as avian influenza. Since the technology associated with genetic transformation and large-scale
propagation is very well established in Nicotiana, the genus has attributes well-suited for the production of plant-made
vaccines. However the presence of potentially toxic alkaloids in Nicotiana extracts impedes their use as crude vaccine
preparations. In the current study we describe a Nicotiana tabacum and N. glauca hybrid that expresses the HA glycoprotein
of influenza A in its leaves but does not synthesize alkaloids. We demonstrate that injection with crude leaf extracts from
these interspecific hybrid plants is a safe and effective approach for immunising mice. Moreover, this antigen-producing
alkaloid-free, transgenic interspecific hybrid is vigorous, with a high capacity for vegetative shoot regeneration after
harvesting. These plants are easily propagated by vegetative cuttings and have the added benefit of not producing viable
pollen, thus reducing potential problems associated with bio-containment. Hence, these Nicotiana hybrids provide an
advantageous production platform for partially purified, plant-made vaccines which may be particularly well suited for use
in veterinary immunization programs.
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Introduction
Transgenic plants are gaining acceptance as a platform for the
production of affordable recombinant proteins in the pharmaceu-
tical industries [1,2]. Since the first manuscript reporting plant-
made vaccine (PMV) production [3], many studies have
demonstrated the value of expressing antigens in plants [4,5].
Advantages associated with using a plant expression system
include the ability to utilize gene splicing to produce multi-antigen
vaccines and the decreased risk of product contamination with
human or animal pathogens. Plant-made heat stable vaccines can
be shipped and stored without refrigeration and have the potential
to be produced in edible plant organs and delivered orally without
the requirement for recombinant protein purification. Encapsula-
tion within the plant cell wall may increase the oral efficiency of
the vaccine and stimulate mucosal and systemic immune
responses, and hence may be effective against respiratory
infectious diseases [6]. Influenza is a respiratory condition in
animals and humans caused by enveloped, segmented, single-
stranded, negative sense RNA members of the Orthomyxoviridae
family of viruses [7]. Avian influenza virus (AIV) can infect a
variety of avian and mammalian species including domestic
poultry and humans, and poses a serious international pandemic
threat [8]. It may be possible to diminish the risk of a pandemic
outbreak of AIV by immunising susceptible farm animals against
the virus. In fact, the first plant-made vaccine (PMV) to be
commercially licensed was a partially purified, injectable poultry
vaccine against Newcastle Disease Virus (NDV) [9]. Production of
cheap and effective vaccines is particularly important for the
developing world where ready access by subsistence farmers to
refrigerated, expensive animal vaccines is often extremely limited.
As current regulations allow crude or partially purified veterinary
vaccine formulations to be administered by injection (http:
//www.aphis.usda.gov/animal_health/vet_biologics/publications/
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istered without requiring antigen purification may make immuni-
zation of large numbers of at risk farm animals economically
feasible.
Several studies have reported the successful plant-based
production of an AIV surface protein, the haemagglutinin (HA)
glycoprotein, using transient transformation in Nicotiana [10,11].
Agrobacterium-mediated transient expression of HA in N. benthamiana
enabled high accumulation (50 mg/kg) of virus-like particles
(VLPs) consisting of HA antigen. These plant-made VLPs were
purified within three weeks of introduction of DNA constructs into
leaf tissues. Mice that were immunised intramuscularly with two
doses, each containing 0.5 mg, of the purified H5-VLPs were
protected against H5N1 influenza virus challenge [10]. Similarly,
a TMV-based, deconstructed viral transient expression system in
N. benthamiana leaf tissues produced a HA yield of 60 mg/g fresh
weight. Following purification, the antigen elicited strong H5-
specific immune responses in mice and displayed high haemag-
glutination inhibition (HI) and virus-neutralizing (VN) antibody
titres. The purified plant-made HA also provided full protection to
ferrets challenged with the A/Indonesia/05/05 influenza virus
[12].
Stably transformed Nicotiana species are also well suited for
producing plant-made vaccines and offer some advantages over
transient production systems. Stable transformation is easily
achieved in Nicotiana and eliminates the need for repeatedly
introducing constructs as well as reducing the potential for batch
variation inherent in transient production systems. Furthermore,
plants such as N. tabacum, grow rapidly and can produce large
amounts of leaf biomass per hectare potentially containing high
concentrations of antigen (reviewed in [13]). Nicotiana species are
not food crops and hence the possibility of contaminating the food
chain is reduced. However, there are some disadvantages
associated with the use of transgenic N. tabacum to produce
vaccine proteins. N. tabacum has the capacity for prolific production
of small seeds which are easily distributed and remain viable in the
soil for many years. Regulations regarding bio-containment may
constrain the use of such a plant as a protein-production system. In
addition, leaf tissues of most species in the genus Nicotiana,
including N. tabacum, can contain substantial quantities of toxic
pyridine alkaloids, particularly nicotine, nornicotine, anatabine
and/or anabasine [14,15]. The levels of alkaloids increase in leaf
tissues of Nicotiana following insect attack or physical damage to
aerial tissues, such as removal of the inflorescences or vegetative
apices [16,17,18,19,20,21,22]. While it is possible that some
metabolic components present in crude leaf extracts have
synergistic, adjuvant effects when combined with antigenic
proteins to improve the immune response [23,24,25], the presence
of alkaloids in vaccine preparations of crude or partially purified
extracts of tobacco leaf tissues may present regulatory hurdles
associated with their use in animals. The requirement to purify the
vaccine would increase the cost of veterinary vaccine production in
transgenic tobacco. Hence, the ability to reduce the seed and
alkaloid production capacity of Nicotiana would enhance the
prospects for utilizing these plants as a vaccine production
platform.
Knowledge relating to alkaloid production in Nicotiana has
increased rapidly in recent years and has facilitated the use of
antisense- or RNAi-mediated technology to down regulate key
alkaloid biosynthesis genes [26,27]. Recently we have demon-
strated the use of double stranded RNA gene-silencing to reduce
or eliminate alkaloid production in leaf tissues of the tree tobacco
Nicotiana glauca, even when plants were wounded or decapitated
[16]. The availability of these transgenic lines provided the
opportunity of crossing them with transgenic HA-producing N.
tabacum to produce an alkaloid-free HA-containing plant whose
leaf extracts would be able to induce an antigen-specific immune
response in animals without purification. Previous research has
indicated that this inter-specific hybrid Nicotiana plant would be
viable and potentially have the advantage of being self-sterile [28].
To test this idea, DNA constructs utilizing two promoter
sequences, the Cassava Vein Mosaic Virus promoter [CsVMV]
or the chimeric octapine synthase-mannopine synthase 4OCS-
DMas promoter [29], and two HA coding sequences (a native or a
plant-optimised sequence) were produced. The HA sequence was
designed by Dow Agrosciences LLC to induce an immune
response against the avian influenza virus. These constructs were
transformed into plants of the aabb genotype of N. tabacum variety
LAFC 53 [22,30]. This LAFC 53 variety (nic1nic2/aabb
genotype) was recently shown to contain mutations in alkaloid
pathway regulatory genes belonging to the AP2/ERF family of
transcription factors [26] and produces less pyridine alkaloid than
its near-isogenic parental line of the Nic1Nic2/AABB genotype
[22]. The HA antigen-producing ability of transgenic N. tabacum
variety LAFC 53 plants containing the various constructs was
assessed and selected individuals were then crossed to A622-RNAi
silenced N. glauca to obtain the HA-producing, interspecific hybrid.
The capacity for pyridine alkaloid synthesis in the interspecific N.
tabacum X N. glauca hybrid was determined and the immunoge-
nicity of the HA crude plant extract was then assessed in mice
trials following subcutaneous injection.
Results
Characterization of plant-made HA protein
To obtain a control sample of plant-made HA protein,
Agrobacterium-mediated transient expression using a deconstructed
viral vector [31] was undertaken in six-week-old N. benthamiana
plants. Up to 23 mg/g fresh weight (FW) of HA were produced in
leaves harvested seven days post infiltration (data not shown).
Purification from 600 g of fresh tissue provided 12.6 mg of HA, a
yield around 90%. The purified HA was used as a positive control
in further analyses. To produce HA in stably transformed plants,
transgenic plantlets of N. tabacum LAFC 53 were generated
containing one of the three expression constructs shown in
Figure 1. These Nt LAFC-HA plants were screened for their ability
to produce HA using capture ELISA. Approximately 80
independent ammonium glufosinate resistant lines for each
construct were recovered, and about half were found to
accumulate HA protein at levels $0.5 mg/g FW. These plants
were selected for further analysis. The mean HA content for each
construct was calculated from these independent Nt LAFC-HA
lines from the ELISA analysis, and demonstrated that the Nt
LAFC-HA plants containing the 4OCS-DMas promoter construct,
pDAB4493, produced significantly higher HA levels (p,0.05)
compared to those produced by plants harbouring the CsVMV
promoter construct, pDAB4492 (Figure 2a). There was no
significant difference (p$0.05) between mean HA content of Nt
LAFC-HA plants transformed with constructs containing either
the native or plant codon-optimized coding region (Figure 2a).
All the glufosinate-resistant stable transgenic Nt LAFC-HA
plants were healthy and showed no obvious phenotypic deviations
from normality. From the independent Nt LAFC-HA lines, two to
three elite plants expressing high HA levels ($10 mg/g FW) as
determined by ELISA were chosen for further analysis.. The
presence of the HA gene was confirmed in these plants using PCR
(data not shown). Western analysis demonstrated that the
monomeric form of the HA protein produced in these elite Nt
Plant Platform for Production of Animal Vaccines
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75 kDa, as did the purified HA control (Figure 2b). The HA
protein can retain dimeric or trimeric conformation on SDS-
PAGE of approximately 150 kDa and 225 kDa respectively, and
these were observed in the extracts from several transgenic plants
and the HA control. At least two of the highest HA expressing Nt
LAFC-HA lines, were chosen from lines containing each of the
constructs and used for creation of the interspecific hybrid plants.
Characterization of the interspecific hybrids
We have shown previously that the 35S-A622-RNAi construct
reduces the high alkaloid levels normally produced by N. glauca
plants to undetectable levels [16]. To reduce the level of alkaloids
produced by the elite Nt LAFC-HA plants, they were crossed with
N. glauca A622-RNAi as described in the methods section. The best
performing hybrid line with respect to high HA levels, based on
the ELISA results, and the lowest alkaloid content, based on the
HPLC data, was selected for further analysis. The parent line of
this hybrid, pDAB4493-8a Nt LAFC-HA contained two copies of
the HA gene (Figure 2c). The same parental pDAB4493-8a Nt
LAFC-HA line was also crossed with wild-type N. glauca to
produce an alkaloid-containing hybrid as a control.
Hybrid seeds germinated with high efficiency (.95%). Glufo-
sinate-resistance confirmed the presence of the HA construct.
These hybrid plants were vigorous with healthy leaves. The shape
and size of the flowers and leaves of the hybrid plants were of
intermediate appearance between both parental species (Figure 3a)
which is characteristic of interspecific hybrids in the genus Nicotiana
[32,33]. To confirm the hybrid nature of these plants, amplifica-
tion of a molecular marker based on variability in intron length
within the Nicotiana nuclear gene family encoding quinolinate
phospho-ribosyltransferase (QPT) (Ryan et al., in preparation) was
undertaken. The sizes of the fragments generated from PCR
analysis of hybrid genomic DNA indicated both QPT gene
paralogues from the N. tabacum and N. glauca parents are present in
the hybrid plants (Figure 3b). The hybrid plants did not set seed,
even after manual application of hybrid pollen, or pollen from
either parental species, to stigmata. Further analysis using
acetocarmine chromosome staining, revealed that pollen of hybrid
plants was empty and shrivelled and incapable of germination,
unlike the pollen of both parental species (Figure 3c). This
indicates that these transgenic hybrid plants are sterile and is in
accord with previous observations made of interspecific hybrids
between N. tabacum and N. glauca, [28,34].
The presence of the HA antigen was confirmed in the Nt LAFC-
HA X N. glauca A622-RNAi hybrid plants (Figure 3d). There was
no significant difference in HA levels in these plants compared to
the Nt LAFC-HA X wild type N. glauca hybrid control plants.
Vegetative shoot regeneration and clonal propagation of the
interspecific hybrid Crossing with the tree tobacco N. glauca
provides the interspecific hybrid with the capacity to grow much
larger than the N. tabacum parent, affording a substantial increase
in biomass production. Under greenhouse conditions, the
interspecific hybrid typically reaches a height of about 3 metres
before flowering (as opposed to about 1.5 metres for N. tabacum)
when grown in 0.5 litre pots. Ease of clonal propagation from
cuttings and a high capacity for vegetative shoot regeneration are
potentially important features in the context of a vaccine
production system involving sterile N. tabacum X N. glauca hybrid
plants. To examine clonal propagation, vegetative cuttings from
the transgenic hybrid plants were dipped in commercial rooting
powder (containing 2 mg/g indolebutryic acid) before transfer to
compost. All of these cuttings rapidly developed roots and gave rise
to vigorously growing clonal plants (data not shown). This is a
feature of both parental species and was therefore expected in the
hybrids.
To test the capacity for vegetative shoot regeneration, the Nt
LAFC-HA X N. glauca A622-RNAi hybrids were decapitated by
removal of the top ,1 cm of their apices. One week after
decapitation, vigorously growing vegetative side shoots were
observed emerging from the top 4–5 nodes on each decapitated
plant. Analysis of these young emerging side shoots showed they
contained no nicotine or anabasine, or indeed any other
methanol-soluble metabolite with a characteristic pyridine alkaloid
spectral absorption profile (Figure 4a). This contrasted with the
high levels of alkaloid (mainly anabasine) of almost 10 mg/g dry
weight in total, in the corresponding control side shoots of the
decapitated Nt LAFC-HA X wild type N. glauca control hybrid
(Figure 4b).
Figure 1. Constructs used to drive expression of HA gene in N. tabacum LAFC 53. CsVMV=the cassava vein mosaic virus promoter. 4OCS-
DMas=a chimeric synthetic promoter. Native HA=the coding region of haemagglutinin from the turkey Wisconsin HA5 AIV strain. Plant-codon
optimised HA=the modified haemagglutinin coding sequence based on plant codon usage frequency. LB and RB represent the left and right T-DNA
borders respectively. VSP 39=the terminator of the soybean vegetative storage protein. PAT=the phosphinothricin acetyl transferase gene.
doi:10.1371/journal.pone.0035688.g001
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mechanical harvesting could be used to scale up the supply of
vaccines or other classes of therapeutic proteins in these plants.
Such a system may provide an additional advantage as clonally
propagated plants may be less susceptible to transgene silencing
that can occur during sexual reproduction and hence provide a
more predictable level of antigen content in the harvested material
[35].
Immunogenicity and efficacy of plant-made HA in mice
To determine if the HA containing crude plant extract from the
interspecific hybrid could invoke an immune responses, the extract
was injected subcutaneously into mice. The previously performed
ELISA analysis of leaf tissue extracts from both the HA-expressing
transgenic hybrids, Nt LAFC-HA X wild type N. glauca, and Nt
LAFC-HA X N. glauca A622-RNAi (Figure 3d), indicated the
presence of 5.4–9.6 mg/g FW of HA. Mice (5–7 individuals per
group) were injected subcutaneously with these crude leaf extracts
adjusted to contain 5 mg HA antigen. Details of the treatment
groups are provided in Table 1. An equivalent amount of purified
HA antigen was used in the positive control treatments. In an
attempt to minimise any distress in the mice injected with the
control tissue extracts that contained pyridine alkaloids, vaccine
doses were calculated to contain less than half of the published
LD50 of nicotine and anabasine [36,37]. Despite these precautions,
some mice injected with samples containing alkaloid exhibited
toxic responses. A stage 1 toxic response [38], consisting of a
noticeable trauma in the first hour following injection, was
observed in one in seven mice of vaccine group E and F following
the first injection. A more severe stage 2 response, composed of
chronic convulsions lasting up to 2 hours was observed in all seven
mice in group E and three of the mice in group F following the
second injection. Only one in seven mice in group E and two in
seven mice in group F showed a similar response after the third
dose. Similar reactions have been observed previously in rats
suffering acute nicotine poisoning [38]. No such symptoms were
observed in animals receiving either purified HA protein or crude
leaf extract from the alkaloid-free transgenic plants.
Serum HA-specific antibody titres in injected mice, as detected
by ELISA, peaked on day 28 post-vaccination. By this time, mice
immunised with HA treatments possessed significantly higher
geometric mean HA-specific serum total IgG titres than their
negative-control counter treatments (p=0.0002) (Figure 5a). No
significant difference was observed between HA-specific IgG titres
induced by the purified HA or crude HA extracts. While the
addition of the adjuvant alum enhanced the response to the
purified HA sample, the antigen-specific immunoglobulin (Ig)
responses to the HA containing crude extracts were similar,
irrespective of the presence or absence of either adjuvant or
pyridine alkaloids.
An examination of the IgG isotypes showed high HA-specific
IgG1 antibody responses to all HA treatments (Figure 5b), with
purified samples eliciting the highest response. The presence of
adjuvant did not significantly increase the immune response
induced. The IgG2a response was low, leading to high IgG1/
IgG2a ratios, ranging from 16.3 to 61.7. The inclusion of adjuvant
did not substantially affect these ratios.
Haemagglutinin inhibition (HI) titres using purified split virus
(Turkey Wisconsin, H5N9) were measured to confirm the
bioactivity of antibodies raised against plant-made HA. Although
purified HA treatments (groups A and B) displayed inhibition of
viruses at somewhat higher dilutions, there was no significant
difference in agglutinating ability between antibodies raised in
mice using any of the plant-made vaccine treatments (Figure 6). All
transgenic treatments displayed inhibition dilutions that were
significantly higher than observed in the negative controls
(p,0.0001) (Figure 6).
Figure 2. Analysis of T0 N. tabacum LAFC 53 plant lines
transformed with HA constructs. 2a. The mean HA content in Nt
LAFC-HA plants transgenic for each construct type quantified using
ELISA analysis. *Mean levels of HA in plants transgenic for pDAB4493
were significantly different (p,0.05; t-test) to those containing
pDAB4492. Nt=non-transgenic N. tabacum var. LAFC 53. Error bars
represent standard error of mean (SEM) (n=40 for plants transgenic for
pCHA; n=45 for plants transgenic for pDAB4492; n=52 for plants
transgenic for pDAB4493), FW=fresh weight. 2b. Western analysis of
leaf extracts from representative Nt LAFC-HA plants. Extracts from
plants containing HA constructs were loaded in central lanes as
indicated. Purified HA was loaded as a control in the left lane whilst leaf
extract from non-transgenic N. tabacum var. LAFC 53 was loaded in the
right lane. All lanes contained 10 mg total soluble protein (TSP). 2c.
Detection of HA transgene in selected elite transgenic lines of N.
tabacum containing the pDAB4493-HA construct. Southern blot
hybridisation of Hind III digested genomic DNA isolated from Nt
LAFC-HA transgenic plants probed with the HA gene.
doi:10.1371/journal.pone.0035688.g002
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the crude alkaloid-free HA-containing samples developed HA-
specific IgG adaptive immune responses and that reducing
alkaloid content had no significant impact on the HA specific
immune responses induced.
The innate immune response in human peripheral blood
mononuclear cells (PBMCs) was also characterised by monitoring
IFNa and TNFa cytokine profiles following overnight incubation
(Figure 7). The cytokines released during innate immune responses
form a foundation to adaptive immune responses [39]. The
cytokine production assay can provide evidence of a possible
adjuvant effect associated with the crude plant extract. A high
TNFa response, accompanied by a low IFNa response can also
indicate the presence of endotoxin. CL75 was used as a control for
elevated TNFa production or a response by TLR8, while
gardiquimod was used as a control for elevated IFNa production
or a response by TLR7. When using human PBMCs, levels of
TNFa below 50 pg/mL and IFNa below 50 pg/mL were taken as
negligible or negative [40]. The purified HA sample produced
very strong TNFa but not IFNa responses. Crude extracts from
transiently expressing agroinfiltrated leaves induced a low if not
negligible TNFa response although this level was significantly
higher than the wild type control (p,0.05). Interestingly, the
extract from the control N. glauca A622-RNAi lines (not producing
HA), resulted in strong TNFa and IFNa responses (Figure 7). The
response observed for the control N. glauca A622-RNAi extract was
mimicked by the Nt LAFC-HA X N. glauca A622-RNAi hybrid
extract, although to a much lesser extent. Our preliminary
experiments involving mouse macrophages deficient for TLR2/4
(data not shown) showed that the extract from N. glauca A622-
RNAi plants induced a strong cytokine response in TLR2/4
deficient cells. Taken together, the results suggest that the innate
immune system may be responding to the presence of an
unidentified component/s in the N. glauca A622-RNAi extract,
other than lipopolysaccharide or endotoxins characteristic of
gram-negative bacteria.
Discussion
The potential for a pandemic outbreak has led to classification
of H5N1 AIV in List A of the l’Office International des E ´pizooties
(OIE; World Organization for Animal Health). AIV is also
Figure 3. Characterisation of N. tabacum X N. glauca hybrids. 3a. Floral and vegetative phenotypes of the hybrid (centre) compared with
parentals. All plants in the bottom panel are eight weeks old. 3b. Molecular evidence for the presence of both parental genomes in N. tabacum X N.
glauca interspecific hybrids. PCR was used to detect species-specific length variability in intron 5 of Nicotiana QPT paralogues. N. tabacum LAFC 53
generates different sized bands from N. glauca. Parental DNA refers to genomic N. glauca and N. tabacum LAFC 53 mixed in vitro. DNA-free refers to
PCR performed without template. 3c. Microscopic analysis of pollen. Panels i–iii show pollen after initial staining with acetocarmine. Panels iv–vi
shows pollen after incubation in pollen germination medium. Flanking panels show pollen from parental species as indicated. Centre panel shows
non-viable hybrid pollen. All scale bars represent 50 mm. 3d. ELISA analysis of HA levels in individual interspecific hybrid plants. Data represents
means of triplicate analysis 6 SEM. DW=dry weight. All lines are derived from To parental Nt LAFC-HA pDAB4493-8.
doi:10.1371/journal.pone.0035688.g003
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animals and hence has substantial economic impact [41].
Recently, attention of the scientific community has focused on
the development of a plant-made vaccine against avian influenza
using transient transformation of Nicotiana [10,11,12,42,43,44,45].
These studies used purified proteins to induce an immune
response thereby avoiding possible negative health consequences
due to the presence of secondary metabolites such as pyridine
alkaloids. While stable transgenic Nicotiana species have potential
as a highly productive, bioreactor species for producing therapeu-
tic and antigenic proteins, allowing rapid vaccine production and
ease of scale-up [13], a reduction in the alkaloid metabolites
produced in Nicotiana may enhance their usefulness. A low-
alkaloid, male-sterile tobacco has been used previously to produce
recombinant interleukin-10 protein [46,47]. However, despite the
low alkaloid characteristics, the potential usefulness of this female
fertile line for large-scale production of antigenic proteins may be
limited as most regulatory authorities would be likely to insist on
repeated manual removal of inflorescences to ensure adequate
environmental bio-containment. Apart from the technical diffi-
culties inherent in ensuring no seed set if such operations were
conducted on a large commercial scale, increased alkaloid
synthesis is likely to occur in such plants as a result of removal
of apices and leaf tissues, albeit at a lower level than in
conventional high-alkaloid tobacco varieties [22]. In the present
study, we included the use of crude leaf extracts of plants from the
low alkaloid variety of N. tabacum LAFC 53 stably transformed with
HA as a control. This variety of tobacco is capable of producing
moderate to high levels of pyridine alkaloid in its roots but
generally contains low alkaloid levels in leaves. However, despite
having relatively low levels of alkaloid, injection of crude extracts
from HA-containing plants of this variety caused some distress in
animals consistent with alkaloid toxicity. In contrast the HA-
producing interspecific tobacco hybrid which has no detectable
alkaloids in the leaf tissues caused no toxicity problems. Moreover,
decapitation of this interspecific hybrid encouraged the rapid
production of vigorously growing side shoots that were also found
to be devoid of alkaloids, indicating that alkaloid levels are likely to
remain negligible even in a field situation where tissue damage is
likely to occur. The sterile nature, the ease of vegetative
reproduction, and the robust side-shoot regenerative capacity of
these genetically altered Nicotiana hybrids makes them attractive
hosts for automated, large scale harvesting of alkaloid-free,
vaccine-containing plant material for animal immunisation
studies. Whether lack of alkaloids would require such transgenic
plants to be protected from increased susceptibility to insect attack
if they were grown on a large scale in open plantations is as yet
unknown and would be a necessary question to address
experimentally if such trials were to proceed.
All plant-made HA treatments in this study produced a
substantial increase in HA antibody titre over the corresponding
negative control treatments. There was no significant difference
between the titres of HA-specific IgG induced by the different
transgenic plant-made HA treatments, therefore the sterile and
alkaloid-free HA hybrid lines have the same capacity as the
purified antigen to induce an HA immune response, without the
induction of a toxic effect. The high IgG1/IgG2a ratios induced
by plant-made HA treatments indicate a strong Th2 immune
response as required for protection against avian influenza [48],
however the Th1 response would need to be improved for better
protection against the virus. This response may be improved by
increasing the HA antigen dose and/or inclusion of a CpG
adjuvant [49]. The biological activity of the HA-induced
antibodies was verified by testing their ability to inhibit
agglutination of purified AIV virus (Turkey, Wisconsin H5N9) to
chicken red blood cells. The level of HI titre obtained is generally
considered to be biologically significant [50,51]. Again, there was
no significant difference between the neutralising ability of
antibodies induced by plant-made antigen from sterile, alkaloid-
free hybrid lines and the antibodies induced by purified or
alkaloid-containing counterparts.
Figure 4. Analysis of interspecific hybrids for alkaloid content. 4a. Chromatograms of the pyridine alkaloid profile in the parental and hybrids
lines after removal of plant apices. (i) Nicotinic acid mononucletide was extracted as a background metabolite in the methanol-soluble fraction, (ii)
Anabasine profile, (iii) Nicotine profile. 4b. Total pyridine alkaloid levels in vegetative regenerating shoots of parental and WT hybrid controls and HA-
containing interspecific hybrid plants. Analysis was undertaken one week after removal of plant apices; graphs represent the mean of three separate
plants per treatment (6 SEM), ND=None Detected. DW=dry weight.
doi:10.1371/journal.pone.0035688.g004
Table 1. Summary of the different experimental groups and candidate vaccine formulations.
Vaccine group* Origin of vaccine Vaccine formulations
A Nicotiana benthamiana agroinfiltrated with HA Purified plant-made HA antigen
B N. benthamiana agroinfiltrated with HA Purified plant-made HA antigen+alum
C Hybrid Nt LAFC-HA x N. glauca A622-RNAi Crude HA plant extract without alkaloid
cC Control Hybrid Nt LAFC x N. glauca A622-RNAi Control plant extract without alkaloid
D Hybrid Nt LAFC-HA x N. glauca A622-RNAi Crude HA plant extract without alkaloid+alum
cD Control Hybrid Nt LAFC x N. glauca A622-RNAi Control plant extract without alkaloid+alum
E Nt LAFC-HA Crude HA plant extract with low alkaloid
cE Control Nt LAFC non transgenic plant Control non transgenic plant extract with low alkaloid
F Hybrid Nt LAFC-HA x WT N. glauca Crude HA plant extract with normal alkaloid
cF Control Hybrid Nt LAFC x WT N. glauca Control plant extract with normal alkaloid
All HA antigen treatments consisted of 5 mg of HA. 20% alum (aluminium hydroxide) was added as an adjuvant where indicated.
*Lower case ‘‘c’’ refers to the control group for each designated HA treatment group.
doi:10.1371/journal.pone.0035688.t001
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immune responses. Once initiated, adaptive immunity is mediated
by specific, clonally distributed B and T lymphocytes that undergo
4–7 days of clonal selection and expansion of relevant cell lines
[52]. During this delay, infection is controlled by the innate
immune response that is mediated through non-clonal recognition
receptors that include the toll-like receptor (TLR) pattern
recognition receptor family. TLRs are cytoplasmic or transmem-
brane proteins that can recognize pathogen-derived ligands and
initiate complex signal transduction cascades [52]. Each TLR
recognizes a diverse range of structurally differing ligands. The
best understood of the TLRs is TLR4 that recognizes bacterial
lipopolysaccharides (or endotoxins) while others such as TLR 3, 7
or 8 are known to be involved in viral nucleic acid recognition.
Engagement of innate immune sensors by pathogens is critical for
the proper mounting of an antibody response and is of paramount
Figure 5. Capacity of HA-containing plant extracts to elicit an immune response. 5a. HA-specific systemic immune response of mice. The
horizontal lines represents the geometrical means of HA specific IgG titres at day 28, while the data points represent IgG titres from individual mice.
Detailed description of treatments is described in Table 1. Solid dots indicate response to samples containing HA antigen. Open circles indicate
responses to samples without HA antigen. A significant difference exits between HA positive samples and control samples (p=0.0002). 5b. Detection
of anti-HA specific IgG isotypes in mice sera on day 28. The horizontal lines represent the geometrical means of IgG isotype titres, while the dots
represent IgG isotype titres from individual mice. Detailed description of treatments is described in Table 1.
doi:10.1371/journal.pone.0035688.g005
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PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e35688Figure 6. Haemagglutination inhibition (HI) titres of sera from immunized mice. The geometrical means of the HI titres are expressed as
reciprocals of the highest dilution of serum that inhibited four haemagglutinin units of virus. Values above the broken line (dilutions of $1:40)
indicates the presence of protective HI titres. A significant difference exits between HA samples and the non immunised control (p,0.0001).
doi:10.1371/journal.pone.0035688.g006
Figure 7. Innate immune response in human peripheral blood mononuclear cells. Cytokine production was measured by specific ELISA,
absorbance 750 nm. Data from biological triplicates representative from two independent experiments involving two different blood donors. IFN,
interferon; TNF, tumor necrosis factor. Gardiquimod and CL75 were used as controls (see methods).
doi:10.1371/journal.pone.0035688.g007
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ability of plant extracts used in this study to induce an innate
immune response, and in particular, to determine if possible
endotoxin contaminations were present. The very strong TNFa
but not IFNa responses observed in our purified plant extract are
the hallmark of endotoxin contamination. Since this was not seen
in the crude transiently produced HA extracts, we believe
contamination of the HA sample occurred some time during the
purification process. The strong response for both TNFa and
IFNa that was induced by the A622-RNAi silenced N. glauca
extract, and to a lesser extent by the A622-RNAi hybrid extract,
indicates the presence of an inducer of the innate immune
response independent of an endotoxin contaminant in these plant
extracts. The induction may have been due to ssRNA present in
the RNAi plants, but these products are unlikely to be stable
enough to be endocytosed and activate endosomal TLR7 and
TLR8 responses. In Nicotiana, the alkaloid and polyamine
pathways share common precursors. The blocking of the
pyrimidine alkaloid pathway due to the absence of A622 activity
is likely to result in a build up of intermediate metabolites and/or
increase in the flux of precursors through the polyamine pathway.
Future work will investigate the nature of the innate immunity
inducer/s present in these extracts. Since polyamines have
previously been reported in the literature to induce innate
immune responses, these are thought to be likely candidates
[54,55]. It should be noted that although previous studies have
observed that innate immune responses act as a foundation to
enhance adaptive immune responses [39], no substantial
difference was observed between the adaptive immune response
resulting from crude HA extracts of the A622-RNAi hybrid lines,
that contain the putative inducer/s of the innate immune system
and the HA extracts from non- A622-RNAi plants (purified HA
extracts, and extracts from non-hybrid/WT hybrid lines). This
may be due to a threshold innate immune response not being
reached by the hybrid line which evoked a lower response than
the N. glauca A622-RNAi line (Figure 7), or the lack of
conservation of the innate immune sensor(s) involved between
human and mouse. Nevertheless, the results indicate the potential
for engineering further enhancement of these hybrid lines for
veterinary vaccine production purposes, with potential self-
adjuvanting properties.
In conclusion, our studies indicate the efficacy of HA-
containing, self-sterile, interspecific Nicotiana hybrids for produc-
tion of plant-made influenza vaccines. Elimination of pyridine
alkaloids in transgenic hybrid plants reduced toxicity of the crude
antigen extracts without adversely affecting plant growth and
productivity or the capacity of the plant extract to illicit an
immune response. Such alkaloid-free N. tabacum X N. glauca A622-
RNAi interspecific transgenic hybrids therefore have potential as a
model vaccine bioreactor system for production of plant-made
vaccines against influenza virus and possibly other infectious
agents. In particular, the use of such a system for animal
immunization studies has potential to improve efficiency of bio-
containment procedures and reduce the need for vaccine
purification which could substantially diminish the cost of
downstream processing.
Lastly, one of the major factors with administering antigens in
plant extracts is ensuring consistency in the dosage levels required
for effective immunization. The ability to use large-scale clonally-
propagated plant material for antigen production has the potential
to provide consistent levels of antigen in the plant extract and
hence address this problem.
Materials and Methods
Production of HA in plants
The HA glycoprotein was produced in Nicotiana leaf tissues
either by transient transfection with a viral-based vector system
(MagnICON) or through stable Agrobacterium-based genetic
transformation using a binary vector. A combination of native
or plant-codon optimized coding regions and the constitutive
promoters: cassava vein mosaic virus (CsVMV) promoter or
synthetic 4OCS-DMas promoter was assessed for the capacity to
produce the HA antigen. The pCHA, pDAB4492 and pDAB4493
binary plasmids are proprietary plant expression vectors belonging
to Dow AgroSciences LLC. The pCHA and pDAB4492 vectors
contain the CsVMV promoter whilst pDAB4493 contains the
4OCS-DMas promoter. Both pDAB4492 and pDAB4493 contain
the plant-optimized coding region of the HA gene (Figure 1). All
plasmids were cultured in Escherichia coli DH5a and electroporated
into Agrobacterium tumefaciens LBA4404 [56]. For preparation of
purified HA, the plant codon-optimised HA coding sequence was
amplified from the construct pDAB4493, using primers with
flanking NcoI and BamHI sites, and ligated into magnICON
plasmid pICH11599 (Icon Genetics) to produce the pICH-HA
sub-clone. Nicotiana benthamiana leaves transiently expressing HA
were produced using A. tumefaciens strain GV3101 transformed with
pICH-HA and co-transformed with the cytoplasm-targeting and
integrase modules of the MagnICON system (Icon Genetics
GmbH, Germany) [31,57,58]. A vacuum infiltration device was
used for this process. Plants were inverted so that their aerial
portion was submerged in 3 litres of A. tumefaciens, OD600 of 0.5
before being inserted into the vacuum infiltration device. A
vacuum was pulled to 25 mm Hg for 1 min, then quickly released.
The plants were returned to the greenhouse and the leaves
harvested ten days post-infiltration (dpi) and stored at 280uC until
processing.
Stable plant transformation
Transgenic plants of Nicotiana tabacum LAFC 53 (a low-alkaloid
variety of aabb genotype) [22,30], containing expression constructs
from pCHA, pDAB4492 or pDAB4493 binary vectors, were
obtained using a leaf disc transformation procedure as described
previously [16]. Independently transformed lines were selected on
medium containing 100 mg/L ammonium glufosinate and
transferred individually to pots of soil when root systems were
well developed. Plants were screened for HA production in leaf
tissues when approximately 10 cm in height using an enzyme-
linked immunosorbant assay (ELISA). Plants expressing high levels
of HA antigen (Nt LAFC-HA) were used in subsequent
experiments.
Genomic DNA extraction for detection of the HA gene in
transgenic plants
Nt LAFC-HA plants expressing high HA levels were selected for
further molecular characterisation. Genomic DNA was extracted
from 100 mg fresh leaves of T0 transgenic lines. Leaf material was
collected and snap frozen in liquid nitrogen before being crushed
to a fine powder with two 3 mm tungsten carbide beads for 1 min
at a frequency of 28/s in a bench-top Qiagen Mixer Mill.
Genomic DNA was then prepared using a standard CTAB
extraction protocol [59]. Genomic DNA (,0.5 mg) plants was used
as template in PCR analysis using transgene-specific primers;
HAF237 (59-GGSAACCCAATGTGTGATGAG-39) and
HAR1071 (59-CCATCCATCWAC CATKCCTTGCC-39) with
an annealing temperature of 52uC and a total of 30 cycles. An
amplicon of 854 bp was anticipated when using DNA from HA-
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using 15 mg of DNA from selected elite transgenic Nt LAFC-HA
plants following digestion with Hind III for both pDAB4492-HA
and pDAB4493 constructs and with Stu I for pCHA-HA. The HA
PCR amplicon of 854 bp noted above was labelled by incorpo-
ration of digoxigenin (DIG)-labelled dCTP using a PCR DIG
Probe Synthesis kit (Boehringer Mannheim, Germany). Probing
and visualization was performed using Roche Applied Science
DIG wash and block buffer set and a DIG Luminescent Detection
Kit. Hybridising bands were detected by exposure of labelled
membranes to X-ray film for 2–5 min.
Purification of reference HA protein
For large scale production of purified plant-made HA,
infiltrated leaf samples were homogenized in protein extraction
buffer (200 mM sodium borate pH 9, 5 mM EDTA pH 8,
20 mM DTT & 2.0% (w/v) sodium deoxycholate) and filtered
to removed cell debris. The lysate was centrifuged at 26,000 g for
30 min and filtered through Whatmann filter paper number 1.
Protein was precipitated by adding 1/3 volume of cold ethanol
(4uC) and stirring overnight at 4uC, followed by centrifugation at
14,000 g for 45 min. The pellet was resuspended in 600 mL of
buffer (50 mM Tris pH 8, 5 mM DTT & 2.0% (w/v) Tween 20)
for 1 hour at 4uC followed by centrifugation at 26,000 g for
30 min. The supernatant was extracted with an equal volume of
diethyl ether twice and the aqueous phase was degassed and
diluted into an equal volume of column buffer contained a final
concentration of 0.5% W/V Tween 20, 20 mM Tris-HCl pH 8,
150 mM NaCl, 0.5% (w/v) CHAPS, 1 mM CaCl2, 1 mM MgCl2
and 1 mM MnCl2.
The soluble protein was purified in a two-step purification
procedure by Green Chemistry Laboratories, Monash University,
Australia using a concanavlin A column and the anion exchange
resin Capto Q (GE healthcare). The soluble protein was loaded
into a 20 mL conA column. The column was eluted with 20 mM
Tris-HCl pH 8, 1 mM EDTA pH 8, 0.1% (w/v) CHAPS, 1 M
NaCl buffer and fractions containing HA were pooled and
dialyzed (10,000 MWCO Snake Skin, Pierce) against 20 mM Tris
pH 8, 1 mM EDTA pH 8 and 0.1% CHAPS at 4uC. The
dialyzate was loaded onto the anion exchange column and eluted
with 20 mM Tris-HCl pH 8, 1 mM EDTA pH 8, 0.1% (w/v)
CHAPS, 1 M NaCl buffer. The purity and quantification of
plant–made HA was determined by HPLC-FLD amino acid
residue analysis and SDS-PAGE.
Crude protein extraction
Crude protein was extracted by homogenising leaf material in
ice-cold extraction buffer [50 mM sodium phosphate, pH 6.6,
100 mM NaCl, 1 mM EDTA, 0.1% Triton X-100, 1 mM PMSF
and Roche EDTA-free Complete Protease Inhibitor Cocktail
tablet] with two 3 mm tungsten carbide beads for 1 min at a
frequency of 28/s in a bench-top Qiagen Mixer Mill. Insoluble
material was removed by centrifugation at 13,000 rpm at 4uC for
5 min. HA content was quantified by capture ELISA.
HA-specific capture ELISA
Briefly, 96-well titre plates were plated with 50 mL per well of
diluted (1:10,000) goat-anti HA polyclonal antibody in phosphate
buffered saline with 0.05% Tween 20 (PBST). The plates were
sealed and incubated overnight at room temperature. All
subsequent incubations were performed at room temperature
and the plates were washed in PBST three times after each
incubation step. Plates were blocked with 5% dry milk (5%
PBSTM) for 90 min. A volume of 200 mL of crude plant extracts
or standard was added per well to the first row of the plate.
Samples and standards were serially diluted two-fold down the
plate using PBS and the plates were incubation for one hour. A
monoclonal mouse anti-HA antibody in PBS (100 mL of 1:2000
dilution) was added to each well and incubated for an hour. The
diluted goat anti-mouse IgG conjugated with horseradish
phosphatase (Sigma) (1:10000 dilution in PBS) was added to the
plates and further incubated for an hour. Detection was performed
using TMB Peroxidase EIA Substrate kit (Biorad) according to the
manufacturer’s directions. The amount of HA expressed in the leaf
was calculated by reference to a standard curve constructed using
purified HA (Benchmark Biolabs). Quantified ELISA data was
converted to microgram of HA per gram of fresh weight. Plant
lines with HA accumulation higher than 0.5 mg/g in fresh leaves
were chosen for further analysis.
SDS-PAGE and immunoblot analysis
Crude protein extracts from transgenic and wild type N. tabacum
plants were resolved by SDS-PAGE followed by western analysis.
Equal volumes of extracts were loaded on precast 10%
polyacrylamide gels (BioRad). 12 ng of purified plant-made HA
was used as the positive control. The separated proteins were then
transferred to a PVDF membrane (hybond-N, Amersham) before
being blocked with filtered 0.1% skim milk in PBS with 0.1%
Tween-20 for 16 hours at 4uC on a rocking platform. The
membrane was processed with Snap i.d (Millipore) according to
manufacturer’s instructions. The primary antibody used was a 1 in
2000 dilution of mouse anti-plant HA mAb in blocking buffer (as
described above). The secondary antibody was goat anti-mouse
IgG conjugated with horseradish phosphatase (HRP) (Sigma)
(1:10,000 dilution in blocking buffer). Detection of reactive protein
bands was performed using chemiluminescent substrate (ECL kit)
(Amersham) according to the manufacturer’s instructions.
Creation and analysis of transgenic interspecific hybrids
Hybridization between parental genotypes was performed with
plants grown in insect-free P2 greenhouse conditions with selected
T0 plants of HA–positive N. tabacum LAFC 53 plants serving as
female. Seed pods developed rapidly and several hundred fully
formed seeds were harvested approximately 3 weeks after
fertilization. Hybrid seed were selected for ammonium glufosinate
and kanamycin resistance to ensure the presence of both the HA
and the A622-RNAi constructs. Growth of plants in hydroponics
and alkaloid analysis of vegetative tissues was undertaken as
described previously [16,22,61]. Pollen viability in hybrid plants
and parental lines was estimated by incubating freshly dehisced
anthers in a few drop of 2% w/v acetocarmine solution and
determining the percentage of stained grains following microscopic
observation. Typically, viable pollen is deeply stained and rounded
whilst non-viable grains appear shrivelled and lightly stained [62].
The ability of fresh pollen grains to germinate in vitro was also
assessed using germination medium [63]. Observations were made
after several hours of incubation in medium at 25uC and pollen
tube growth was determined under light microscopy Axioskop
(Zeiss). Photographs were taken using a Zeiss Axiocam digital
camera using Axio Vision software.
Immunisation of mice with HA antigen
Inoculum preparation. Transgenic and wild type freeze
dried leaf powder was resuspended in PBS and centrifuged at
12,000 rpm in a Sorvall centrifuge on the immunization day. 20%
alum (aluminium hydroxide - Sigma) was added to the designated
extracts (Table 1) and incubated for 30 min on ice before dose
delivery. The HA vaccines contained 5 mg of purified HA (without
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or normal levels of alkaloid). For crude leaf extract injection, doses
containing #50% LD50 of each alkaloid (,100 mg nicotine;
,3000 mg anabasine) [36,37] were delivered. An equivalent
amount of alkaloid was injected in the control wild type crude
leaf extract treatment. Mice were maintained under conditions
approved by the Animal Ethics Committee, School of Biological
Sciences, Monash University. Female C57BL/6J mice, six to
eight-weeks-old were used to test the immunogenicity of the plant-
made HA. Mice were housed in individual cages provisioned with
water and standard food and monitored daily for health and
condition. Mice were acclimatised for four days during which time
they were randomly assigned to ten groups comprising five to
seven mice each (Table 1). Groups of mice were subcutaneously
injected with 5 mg of purified HA or non-purified plant-made HA
leaf extract (with or without 20% of aluminium hydroxide as
adjuvant) on days 0, 7 and 14 in treatments as listed in Table 1.
After inoculation, mice were observed for any post-immunization
response before being returned to the animal house. Serum
samples were collected through tail tipping on days 24, 8, 15 and
cardiac puncture after CO2 inhalation on day 28. Blood samples
were allowed to clot at room temperature for one hour before
incubation at 4uC overnight. The samples were then centrifuged at
4uC for 10 min at 2500 rpm and the serum (top layer) removed to
a new centrifuge tube and stored at 220uC.
Analysis of the immunogenicity of plant-made HA in
mice
Endpoint titre ELISA was performed to determine the anti HA-
specific IgG response in mouse sera. High-binding 96-well ELISA
plates were coated with 50 mLo fH A( 1mg/mL) in carbonate/
bicarbonate coating buffer (15 mM NaCO3, 35 mM NaHCO3,
0.02% NaN3, pH9.6). The plate was placed at room temperature
for one hour then further incubated at 4uC overnight. All
subsequent incubations were performed at 37uC and the plates
were washed in PBST three times after each incubation step.
Blocking buffer (5% skim milk in PBS with 0.05% Tween 20) was
added to the plate and incubated for 90 min. Serum samples were
diluted in 1:100 in sample buffer (1% skim milk in PBS with 0.05%
Tween 20) and added to the first row of the plate, followed by a
two-fold serial dilution in PBS down the plate and incubated for
2 hours. The diluted goat anti-mouse IgG conjugated with
horseradish phosphatase (Sigma) (1:5000 dilution in sample buffer)
was added to the plate and further incubated for an hour.
Detection was performed using TMB Peroxidase EIA Substrate kit
(Biorad) according to the manufacturer’s directions.
Rabbit anti-mouse class and subclass antibodies from mouse
monoAB ID kit (HRP) (Invitrogen) were used for isotyping mouse
immunoglobulins (IgG1 and IgG2a,) in sera samples as per the
manufacturer’s instructions. Absorbance was read at 405 nm using
a ThermoMax Microplate reader. Haemagglutination inhibition
(HI) assays were carried out as described [64] with some
modifications. Briefly, sera from immunized mice were diluted at
1:10 and heat inactivated in PBS at 56uC for 30 min. Chicken red
blood cells (CRBC) in Alsever’s solutions (kindly provided by Dr
Lori Brown, Melbourne University) were washed three times in
PBS and adjusted to the final concentration of 1% in PBS. The
purified split AIV virus (H5N9 Dow AgroSciences, Indianapolis,
USA) was diluted to four haemagglutinin units (HAU) in PBS as
standard antigen. In round-bottomed polystyrene 96-well micro-
titre plates, the diluted heat-inactivated mice sera were added to
the first well and two-fold serially diluted down to the final well of
the plate, then 4HAU of virus (1:1000) was added to all the wells
except the CRBC control wells. Plates were incubated at room
temperature for 30 min, and 1% CRBC in PBS was added to all
wells and further incubated for 30 min at room temperature.
Plates were then tilted at about 60u and wells were observed for
agglutination. The HI titre was defined as the reciprocal of the
greatest dilution of serum causing complete inhibition of
agglutination by 4 HAU of antigen.
Detection of cytokines production
Transgenic and wild type freeze dried leaf powder was
resuspended in PBS and centrifuged at 12,000 rpm. Cleared
supernatant was used for the analysis as described in [40]. Freshly
isolated peripheral blood mononuclear cells (PBMCs) from healthy
blood donors were plated in 150 uL RPMI medium supplemented
with 5% fetal calf serum and incubated for 4 hours at 37uC (150–
200,000 cells per well of a 96 well plate). 50 uL of plant extract
were added to each well and incubated for 18 hours. Supernatants
were subsequently collected and IFNa and TNFa levels quantified
using reported procedures with specific ELISA assays [40]. CL75
also known as 3M-002 (human TLR8 agonist and mouse TLR7
agonist, Thiazoquinoline) and Gardiquimod (human TLR7
agonist, imidazoquinoline), were purchased from Invivogen (San
Diego, CA) and used at a final concentration of 1 mg/mL (3M-002
and Gardiquimod).
Data transformation and statistical analysis
The starting point for the cut-off dilution determining a ‘‘no
response’’ was established by determining the first dilution point of
each pre-bleed sample where readings plateaued to a slope of less
than 0.05. The endpoint titre was estimated as the reciprocal of
the highest dilution of the sera that had $0.1 OD450 above the
non-treated (negative control) mouse sera. The geometric mean
titre (GMT) of these starting points was calculated for each
treatment group. GraphPad Prism 5 was used for all statistical
analyses performed in this study. Chi squared tests were used to
determine the statistical significance between means or medians
using probabilities of p,0.05 as the limit for observed differences
to be considered significant. A two-tailed unpaired t-test was
performed to evaluate the statistical difference between two groups
of plant or animal data.
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